According to the new research report “Oligonucleotide Synthesis Market by Product & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical & Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) – Global Forecast to 2019″ published by MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected to reach $1,712.1 Million by 2019 from $1,070.7 Million in 2014, growing at a CAGR of 9.8% from 2014 to 2019..
Browse 84 market data tables and 40 figures spread through 185 pages and in-depth TOC on “Oligonucleotide Synthesis Market”
Based on products and services, the market is broadly segmented into equipment, reagents, and synthesized oligonucleotides. Among these segments, the synthesized oligonucleotides market segment is expected to register the highest growth rate during the forecast period, owing to the increasing number of applications of synthesized oligonucleotides in research, diagnostics and therapeutics; and a growing demand for custom oligos.
The market by applications is classified into diagnostics, research, and therapeutics. Research applications are further segmented into PCR, qPCR, sequencing, gene synthesis, and others. The therapeutics market is further segmented into DNA/antisense oligos, RNAi, aptamers, and others. In terms of applications, the research segment commanded the largest share in 2014, while the diagnostics segment is forecasted to be the fastest-growing segment in the Oligonucleotide Synthesis Market. By end users, the market is segmented into academic research institutes, pharmaceutical and biotech firms, and diagnostic labs. Academic research institutes contributed the major market share in 2014; however, diagnostic laboratories are expected to be the fastest-growing end user segment during the forecast period.
Based on geography, the global Oligonucleotide Synthesis Market is segmented into North America, Latin America, Europe, Middle East and Africa, and Asia-Pacific (APAC). North America is expected to account for the largest share of the market in 2014. However, Asia-Pacific is poised to grow at the highest CAGR during the forecast period, owing to increase in research and development activities, rising R&D funding and growing availability of synthesized oligos in the region.
For the seventh consecutive year, Rising Medical Solutions (Rising) has earned a spot on Inc. magazine’s Inc. 500|5000 list, an exclusive ranking of the nation’s fastest-growing private companies. The honor roll represents the most comprehensive look at a vital component of the economy—America’s independent businesses. Companies such as Microsoft, Zappos, Pandora, Patagonia, Jamba Juice, Under Armour, Oracle, and other notable alumni have been members of the Inc. 500|5000.
The 2014 Inc. 500|5000 is ranked according to percentage of revenue growth when comparing 2010 to 2013. To qualify, companies must have been founded and generating revenue by March 31, 2010. They have to be US-based, privately held, for profit, and independent — not subsidiaries or divisions of other companies — as of December 31, 2013. The minimum revenue required for 2010 is $100,000; the minimum for 2013 is $2 million. Complete results of the Inc. 500|5000 can be found at inc.com.
Inc. 500|5000 companies demonstrate impressive results. Over the last three years, their average growth rate was 516 percent with collective revenue of $211 billion, and 505,000 new jobs generated.
Beyond Rising’s own direct job creation, the company’s financial impact on America’s healthcare system is roughly equivalent to 150,877 years of employment added back to the economy. Considering the country’s healthcare challenges, Rising’s ability to improve patient outcomes, increase efficiencies, and reduce billing waste provides tangible advancements to a system in need.
A new study published in the Journal of American Geriatrics Society found that house calls to elderly patients with chronic conditions keep healthcare costs down by reducing the need for expensive emergency room visits. The patients who utilize this care are some of Medicare’s most costly patients with multiple chronic conditions and difficulty managing medication and understanding when preventative care is needed.
The house call program at MedStar Washington Hospital Center, led by Dr. Eric DeJonge, Chief of Geriatrics at MedStar Washington Hospital Center, sends primary care doctors into the homes of some of Washington’s sickest patients. Home visits allow for the doctors to see the patient in their element and get a better sense of the patient’s overall health. The study shows that patients who were provided care in the home had 20 percent fewer emergency room visits and saved Medicare $8,477 per patient over a two year period.
The Medicare home health benefit currently serves 3.5 million senior and disabled Americans who, due to their medical condition, are qualified as homebound and receive skilled care in the comfort of their own homes. Unfortunately, due to recent funding cuts to Medicare, 1.3 million of these patients are at risk of losing access to this critically important service.
Starting on January 1, the Centers for Medicare and Medicaid Services (CMS) began implementing a four year, 3.5 percent annual cut to the Medicare home health benefit, that will slash a total of 14 percent from funding. CMS itself conceded this cut will leave “approximately 40 percent” of providers operating at a net loss by 2017.
Buckeye Health Plan (Buckeye), formerly known as Buckeye Community Health Plan, today announced a new name and look designed to project the innovative, customer-centered mission and goals of the company.
During the past few years, Buckeye has experienced growth in its member base and has expanded across the State of Ohio. The name change and new brand identity will be phased into marketing materials beginning in September, 2014.
Capital BlueCross has long supported programs that increase access to health care and health coverage for our community. This tradition of service continues through our work with the Children’s Health Insurance Program and most recently with our involvement in Governor Corbett’s proposed Healthy Pennsylvania plan to cover many uninsured individuals.
We were proud to be a selected plan by the Commonwealth of Pennsylvania to potentially serve our community through Healthy PA. With the news today the program has been approved by the U.S. Department of Health and Human Services, we congratulate Governor Corbett and Public Welfare Secretary Mackereth on this important milestone.
Capital BlueCross looks forward to continuing our role to increase access to health care in central Pennsylvania and the Lehigh Valley.
SOURCE Capital BlueCross
AARP Pennsylvania released the following statement in response to federal officials today approving a waiver to expand Medicaid for Pennsylvania:
“AARP Pennsylvania is pleased that an agreement has been reached to provide health coverage to more than 500,000 hard-working Pennsylvanians – including 90,000 residents age 50-64 – many of whom are either between jobs or in jobs without health coverage. AARP Pennsylvania was one of many groups encouraging the state over the last two years to close this coverage gap, and we are pleased that so many state residents will not have to wait much longer to get the coverage they need. The final agreement is responsive to many of the concerns AARP Pennsylvania expressed in our comments, but some concerns remain. We look forward to reading the important details of the final agreement and working with state and federal officials as this process moves forward.”
Edison Nation Medical, the premier healthcare innovation marketplace, today announced a worldwide search for product ideas to improve the health and wellness of the senior population. Promising ideas uncovered through the 6-month search (www.EdisonNationMedical.com/Seniors) will be presented to leading medical device manufacturers and healthcare retailers with whom Edison Nation Medical has partnered to improve the lives of individuals age 65 and older.
The objective of the search is to uncover ideas for products, devices, technologies or apps that improve the quality of life and the ability to maintain independence for seniors. Senior health and wellness products cover a broad spectrum of product categories, including (but not limited to):
– Products that assist with daily living activities
– Health monitors
– Medication management systems
– Products that improve safety and mobility
– Senior-friendly portable products and devices
The population of older Americans has been expanding rapidly ever since Baby Boomers began turning 65 — from 43.1 million in 2012 to an estimated almost 70 million in 2030. By 2030, one in every five (20%) Americans will be over the age of 65, which is nearly double the 12% in 2000, according to the “The State of Aging and Health in America” special report issued by US Centers for Disease Control and Prevention (CDC). The US Administration on Aging’s 2012 survey states that 36% of people age 65 and over report some type of disability including:
Independent living difficulty 15.8%
Self-care difficulty 8.87%
Ambulatory difficulty 23.1%
Cognitive difficulty 9.3%
Vision difficulty 6.5%
Hearing difficulty 14.7%
Born out of collaboration with Carolinas HealthCare System (the second largest public health system in the United States), Edison Nation Medical’s mission is to create more effective, more efficient and safer healthcare through open innovation. The company makes this a reality by providing a clear and easy pathway through which anyone — physicians, nurses, entrepreneurs, even patients and caregivers — can submit a medical invention idea for full evaluation and potential commercialization.
Edison Nation Medical encourages patients, caregivers, clinicians, designers and any other innovators from around the world to submit ideas through the organization’s confidential portal. Joining Edison Nation Medical is free and all ideas are vetted through an in-depth review process led by Edison Nation Medical’s team of medical, product development and legal experts. The end goal is to commercialize each qualified product idea and, when successful, licensing royalties or revenues are shared with the inventor.
For more information or to submit an idea, go to www.EdisonNationMedical.com/Seniors.
Nonin Medical, Inc., the inventor of finger pulse oximetry and a leader in noninvasive medical monitoring, today announced that the Food and Drug Administration (FDA) has cleared the Nonin Model 3231 OEM/eHealth finger pulse oximeter for use in the United States. The finger pulse oximeter plugs into a telemedicine hub or kiosk through a USB connector and measures oxygen saturation and pulse rate in pediatric to adult patients. The Model 3231 received EU certification last year.
The Model 3231 features accuracy advantages, including:
– Nonin’s clinically proven PureSAT® Pulse Oximetry (SpO2) technology, which utilizes intelligent pulse-by-pulse filtering to provide precise oximetry measurements—even in the presence of motion, dark skin tones, low perfusion, rapid SpO2 changes and other challenging conditions. PureSAT automatically adjusts to each patient’s condition to provide fast and reliable readings that clinicians can act on.
– Exclusive Nonin CorrectCheck™ technology, which provides feedback via a digital display if the patient’s finger is not placed correctly in the device. CorrectCheck is helpful since improper finger placement may lead to incorrect readings.
– SmartPoint™ capture, an algorithm developed by Nonin that automatically determines when a high quality measurement is ready to be stored. This helps to ensure that each reading transmitted by the Model 3231 is accurate.
Nonin received FDA clearance in September 2013 for its wireless version of the product, the Nonin Bluetooth® Smart Model 3230 finger pulse oximeter.
For more information about Nonin’s Model 3231 and 3230 finger pulse oximeters for eHealth/OEM applications, visit nonin.com/ehealth.
EndoChoice® today announced David Gill has joined the company as Chief Financial Officer. The company also announced it has been recognized for the fifth consecutive year as one of the fastest growing companies in the U.S. by Inc. Magazine.
The continued rapid growth at EndoChoice has been fueled by the success of the company’s wide range of products and services purposefully designed and built for gastroenterologists. “We are in business to serve the gastroenterology caregiver and this unprecedented growth is recognition that our efforts are appreciated,” said Mark Gilreath, Founder and CEO of EndoChoice. “As a result of our expansion and plans for the future, it became important to have a CFO of David’s tenure and experience to guide us through our next growth opportunities,” Gilreath added.
David Gill has been the CFO of four public companies and led the IPO’s of Interland, CTI and NxStage. He joins the company as sales of the new Fuse® Full Spectrum Endoscopy® system have accelerated. “Although colonoscopy is considered the best tool to fight colon cancer, numerous clinical studies have shown this disease continues to plague populations around the world because not everyone is routinely screened and traditional endoscopes miss up to 40% of pre-cancerous polyps. I am excited to join the EndoChoice team and be part of the revolution Fuse is bringing to gastroenterology care,” said Gill.
Endoscopes are thin flexible tubes with imaging capabilities that doctors use to view the upper and lower GI tracts of their patients. The Fuse system uses three small cameras at the tip of a flexible GI endoscope, as compared with one at the tip of a standard, forward-viewing endoscope. With a wider 330 degree view, physicians using Fuse see nearly twice the surface area and anatomy, including behind and into folds where colon cancer causing polyps often hide. A recent clinical study found that Fuse detected 69% more pre-cancerous polyps versus the standard colonoscope. As a result, informed patients are beginning to ‘insist on Fuse’ for their next colonoscopy.
In recognition of the increased risks that seniors have of developing health complications from the flu, pneumonia, shingles and other illnesses, CVS/pharmacy® and MinuteClinic® have declared September to be Senior Vaccination Month. Because people’s immune systems weaken as they age, it is important that adults ages 65 years and older stay up to date on their vaccinations. CVS pharmacists and MinuteClinic nurse practitioners and physician assistants will be raising awareness about the importance of vaccinations for their senior patients throughout the month.
All 7,700 CVS/pharmacy locations and all 900 MinuteClinic locations inside select CVS/pharmacy stores can administer vaccinations to patients to help protect them against the flu and other illnesses every day with no appointment needed, including evening and weekends. In addition to flu and pneumonia vaccinations, other shots such as the shingles vaccine are available at CVS/pharmacy and Hepatitis vaccines are available at MinuteClinic.
In addition to the regular flu shot that is recommended by the Centers for Disease Control and Prevention (CDC) for everyone who is at least six months old, all CVS/pharmacy and MinuteClinic locations also offer the Fluzone® High-Dose vaccine for people 65 years and older. Fluzone High-Dose contains four times the antigens as the seasonal flu vaccine and is designed to provide a stronger immune response in people 65 years and older.
A recent consumer survey by CVS/pharmacy showed that three in five adults in the U.S. are not aware of the importance of the high dose flu vaccine in preventing the flu for adults ages 65 and up. The survey also showed that nearly one in three Americans say they have a role in helping an elderly family member or loved one make health care decisions, including whether to get a flu shot.
Marc Serchia, 56, is waiting on a miracle, and if the doctors are correct he doesn’t have much more time. At the age of 39, Marc suffered a massive heart attack, faced a 5-hour surgery to repair blocked arteries, and died on the surgical table six separate times. Unbelievably, he survived, but with a severely damaged heart. Doctors wouldn’t put him near the top of the heart transplant list because they didn’t think he’d live to find a match. Defying the odds, Marc has lived 17 years by eating healthy, making daily changes, and his sheer will to survive.
The damage to his heart is extensive. A normal, healthy heart has an ejection fraction — how much the heart compresses to circulate oxygenated blood to the body — between 50-70%. In September 2013, Marc’s ejection fraction was 13%, and doctors were — and still are — amazed he is still standing.
After applying to the Cell Surgical Network (CSN), he was accepted into the program, with one large roadblock in the way — insurance does not cover stem cell therapy as it is seen as experimental, and Marc is unable to work per his doctors’ orders. Marc’s daughters rallied his friends, neighbors, even strangers, and after raising $7,000 of the $35,000 needed for treatment, Marc received a stem cell therapy treatment at the Silicon Valley Stem Cell Treatment Center in January 2014. The process entails doctors harvesting Marc’s own stem cells from his body fat, which are then spun in a centrifuge where the stem cells are separated, then mixed in a saline IV drip, and returned to Marc. After three months, his ejection fraction rose to 16-18%. Doctors say Marc can have stem cell therapies every 3-4 months, but he has been unable to have another due to lack of funding.
Ideally, Marc would like to have his next treatment at the Stem Cell Rejuvenation Center in Phoenix, Ariz. Doctors take more of his fat cells during a single treatment, thus returning even more stem cells to Marc’s body.
Marc’s goal is to not only see his grandchildren grow up, but to help doctors in their research of stem cell therapy. With high-profile athletes like NFL quarterback Peyton Manning and MLB pitcher Bartolo Colon completing stem cell therapies, Marc hopes to join them in spreading the message of stem cell therapy and proving its benefits so patients can demand insurance companies cover the procedures. Marc may not be a famous sports hero with the salary to match, but he is a hero to his family.
This release was previously published on the Mountain Democrat.
Fundraisers are ongoing at the following links:
Important information on stem cell treatments and therapies can be found at:
International Cellular Medicine Society — www.cellmedicinesociety.org
Silicon Valley Stem Cell Treatment Center — www.svstemcell.com
Patients for Stem Cells — www.patientsforstemcells.org
Stem Cell Rejuvenation Center — www.the-stem-cell-center.com
Donna Palen/Marc Serchia
SOURCE Marc Serchia
US News & World Report is out with their rankings of the best hospitals according to their own survey. For the first time, the Mayo Clinic in Rochester, Minnesota, claimed the No. 1 spot, followed by Massachusetts General Hospital and Johns Hopkins Hospital. Memorial Sloan Kettering Cancer Center is No. 1 in cancer and the Cleveland Clinic is 1st in cardiology & heart surgery.
The 2014-15 Honor Roll
1. Mayo Clinic, Rochester, Minnesota
2. Massachusetts General Hospital, Boston
3. Johns Hopkins Hospital, Baltimore
4. Cleveland Clinic
5. UCLA Medical Center, Los Angeles
6. New York-Presbyterian University Hospital of Columbia and Cornell, New York
7. Hospitals of the University of Pennsylvania-Penn Presbyterian, Philadelphia
8. UCSF Medical Center, San Francisco
9. Brigham and Women’s Hospital, Boston
10. Northwestern Memorial Hospital, Chicago
11. University of Washington Medical Center, Seattle
12. (tie) Cedars-Sinai Medical Center, Los Angeles
12. (tie) UPMC-University of Pittsburgh Medical Center
14. Duke University Hospital, Durham, North Carolina ?
15. NYU Langone Medical Center, New York
16. Mount Sinai Hospital, New York
17. Barnes-Jewish Hospital/Washington University, St. Louis
Here are the full rankings:
U.S. News 2014-15 Best Hospitals Rankings
For the full list of national rankings by specialty, visit www.usnews.com/best-hospitals.
Top-Ranked Hospitals in Cancer
Memorial Sloan Kettering Cancer Center, New York
University of Texas MD Anderson Cancer Center, Houston
Mayo Clinic, Rochester, Minnesota
Dana-Farber/Brigham and Women’s Cancer Center, Boston
Johns Hopkins Hospital, Baltimore
University of Washington Medical Center, Seattle
Massachusetts General Hospital, Boston
UCSF Medical Center, San Francisco
UCLA Medical Center, Los Angeles
Stanford Hospital and Clinics, Stanford, California
Top-Ranked Hospitals in Cardiology & Heart Surgery
Mayo Clinic, Rochester, Minnesota
New York-Presbyterian University Hospital of Columbia and Cornell, New York
Duke University Hospital, Durham, North Carolina
Brigham and Women’s Hospital, Boston
Massachusetts General Hospital, Boston
Hospitals of the University of Pennsylvania-Penn Presbyterian, Philadelphia
Cedars-Sinai Medical Center, Los Angeles
St. Francis Hospital, Roslyn, New York
Mount Sinai Hospital, New York
Top-Ranked Hospitals in Orthopedics
1. Hospital for Special Surgery, New York
2. Mayo Clinic, Rochester, Minnesota
3. Cleveland Clinic
4. Hospital for Joint Diseases, NYU Langone Medical Center, New York
5. Massachusetts General Hospital, Boston
6. Rush University Medical Center, Chicago
7. Cedars-Sinai Medical Center, Los Angeles
8. Thomas Jefferson University Hospital, Philadelphia
9. (tie) Beaumont Hospital, Royal Oak, Michigan
9. (tie) Duke University Hospital, Durham, North Carolina
The CDC (Centers for Disease Control) is confirming that a man is being treated for Middle East Respiratory Syndrome at Dr. P. Phillips Hospital in Orlando, Florida. This is the second case that has been confirmed in the United States, another case has been confirmed in Indiana.
CDC officials told Click Orlando that the patient was working in a facility in Saudi Arabia that was caring for another MERS patient. Apparently he contracted the disease while caring for another Middle East Respiratory Syndrome patient in Saudi Arabia.
In a USA Today article, “CDC officials cautioned that while the patient felt the symptoms of the MERS virus while traveling from Saudi Arabia, it was not known if the patient was infectious at that time.”
There have been 538 lab-confirmed cases of MERS-CoV worldwide, including 145 deaths attributed to it; the majority of those cases occurred in Saudi Arabia according to the CDC.
Middle East Respiratory Syndrome (MERS) is viral respiratory illness first reported in Saudi Arabia in 2012. It is caused by a coronavirus called MERS-CoV. Most people who have been confirmed to have MERS-CoV infection developed severe acute respiratory illness. They had fever, cough, and shortness of breath. More than 30% of these people died.
Image of map showing countries in Arabian Penninsula with and without confirmed MERs as detailed on this page.So far, all the cases have been linked to countries in the Arabian Peninsula. This virus has spread from ill people to others through close contact, such as caring for or living with an infected person. However, there is no evidence of sustained spreading in community settings.
Amgen (NASDAQ: AMGN) and AstraZeneca recently announced that the Phase 3 AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor. Primary endpoints were patients achieving at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75), and patients achieving clear or almost clear skin at week 12 according to the static Physician Global Assessment (sPGA 0 or 1).
A significantly higher proportion of patients treated with brodalumab achieved a PASI 75 response (primary endpoint), as well as PASI 90 and PASI 100 responses at week 12 (secondary endpoints) compared to placebo. Results showed that 83.3 percent of patients in the 210 mg group and 60.3 percent of patients in the 140 mg group achieved PASI 75 responses compared to placebo (2.7 percent). Results also showed that 70.3 percent of patients in the 210 mg group and 42.5 percent of patients in the 140 mg group achieved PASI 90 responses compared to placebo (0.9 percent). Further, 41.9 percent of patients in the 210 mg group and 23.3 percent of patients in the 140 mg group achieved PASI 100 responses compared to placebo (0.5 percent). Of the 661 patients enrolled in this study, 46 percent reported prior biologic use and 28.7 percent weighed more than 100 kilograms (kg) at baseline (mean weight for the study population was 90.8 kg).
A PASI score is a measure of psoriatic plaque redness, scaling and thickness and the extent of involvement in each region of the body. Treatment efficacy is often measured by the reduction of PASI from baseline (i.e., a 75 percent reduction is known as PASI 75, a 90 percent reduction is known as PASI 90 and PASI 100 is total clearance of skin disease).
The most common adverse events that occurred during the placebo-controlled period in the brodalumab group (more than 5 percent of participants) were nasopharyngitis, upper respiratory tract infection and headache. Serious adverse events occurred in 1.8 percent of patients in the 210 mg group and 2.7 percent of patients in the 140 mg group compared to 1.4 percent for placebo during the placebo-controlled period.
Eisai Inc. will add more than 200 new contract sales representatives to its Metabolic Business Unit, bringing the total sales force for BELVIQ® to approximately 600, triple the size from when the FDA-approved prescription therapy for chronic weight management became available in June 2013. This expansion, which becomes effective on July 1, 2014, will allow Eisai to reach approximately 90,000 physicians.
The increase in sales representatives follows Eisai’s recent launch of a national television advertising campaign which encourages those who continue to struggle with their weight to speak to their doctor about the potential of BELVIQ, when combined with diet and increased activity, to help them lose weight and keep it off. (To view the advertisement for BELVIQ, visit http://www.multivu.com/mnr/7161051-eisai-launches-national-television-campaign-belviq-lorcaserin-hcl-civ)
In honor of National Women’s Health Week (May 11-17), Women’s Health Magazine, the fastest-growing international women’s lifestyle and wellness magazine, is teaming up with the Emmy®-winning daytime syndicated series, The Doctors (check local listings), to encourage women across the country to make their health a priority and bring vital information to the masses during this important week.
To promote the week-long initiative, the May issue of Women’s Health, on sale now, features a four-page spread highlighting instant health upgrades with exclusive advice from The Doctors co-hosts Travis Stork, M.D., Rachael Ross, M.D., Ph,D., Jennifer Berman, M.D., Jennifer Ashton, M.D. and Ian Smith, M.D. In the “45 Instant Health Upgrades” article, the experts discuss ways to improve one’s physical and mental health in all aspects of their life, including sexual health, relationships, nutrition, sleep, oral care, stress and fitness.
In conjunction with the May issue feature, The Doctors will include daily segments from May 12-16, during which the show hosts and Women’s Health editors will reveal health and wellness upgrades to showcase more ways to take advantage of National Women’s Health Week.
CSL Limited (ASX:CSL), parent company of CSL Behring which is based in King of Prussia, PA, recently opened the CSL Behring Biotechnology Manufacturing Facility in Melbourne, Australia. The new facility, located adjacent to the site’s manufacturing plant for plasma products, is the centerpiece of CSL’s $250 million expansion at its Broadmeadows site and will play an increasingly important role in the company’s global operations, particularly in the late-stage development of new types of hemophilia products. It is one of the largest and most advanced facilities of its kind in the world and will produce novel recombinant therapies on a large scale for international clinical trials.
The company’s recombinant factor development programs, which comprise the AFFINITY trial and the PROLONG trial for the study of therapies to treat hemophilia A and B, respectively, are central to its long-term growth plans. Several candidates in these trials are showing promise, including rVIII-SingleChain, rIX-FP, and rVIIa-FP.
More than 15 million American adults and five million children over the age of five suffer from high discomfort or exhibit needle-phobic behavior when faced with getting a blood draw or injection, according to results from a new study, with the overwhelming majority of those studied – 75 percent adults and 91 percent children – naming “pain” as the component they most feared.
Clinically known as blenophobia, the condition is defined as a fear of needles, and includes the fear of pain felt during injections and blood draws. Pain associated with needle sticks leads directly to fear and anxiety, according to the study. The phobia presents a widespread public health challenge since a patient’s behavior is often influenced by their fears – and in extreme cases – affects their ability to receive necessary medical care.
“Blood tests are one of the most important diagnostic tools modern medicine has at its disposal, but if patients are reluctant, or even actively avoid blood draws, then we need to find ways to alleviate the pain and discomfort or other causes keeping them from getting these procedures,” said Mark Dursztman, M.D., Clinical Assistant Professor of Medicine, Weill Medical College of Cornell University, and Assistant Attending Physician, The New York Presbyterian Hospital, Cornell Campus. “The fear of needles and needle stick pain is a real and significant health problem, one that needs to be addressed.”
The survey, sponsored by Vyteris Holdings, Inc. (OTCBB: VYHN), a leading developer of drug delivery products, was conducted to learn more about the incidence and prevalence of high discomfort and needle phobic behavior around routine blood draws and injections. It found that slightly more than half the general population either had or were requested to have a blood draw or injection in the past six months. Fourteen percent, or approximately 15 million adults, identified themselves as being either needle phobic or having high discomfort around getting their blood drawn.
Of those 15 million needle-phobic adults, approximately 3.5 million indicated they had refused a blood draw or chose not to receive a recommended injection at some point in their life. Twenty five percent indicated that the consequences of these refusals were varied and serious, both from a health and economic standpoint, and directly impacted the patient’s quality of life. Over half of the respondents indicated that they did not receive necessary medical care because of the refusal, or made a change in the kind of care they were receiving. Some lost job offers, others did not receive insurance coverage and some were denied admission to school because of the refusal to get blood work done.
“Needle phobia has a direct impact on my ability to deliver necessary healthcare services, and is an important public health issue,” said Dursztman. “The findings underscore how widespread the issue is, and directly correlate to my personal experience as a physician dealing with patients. Needle phobia can be a significant impediment to understanding a patient’s complete health profile. The healthcare community needs to advance more solutions to deal with needle stick pain.”
The survey also found approximately five million children between the ages of five and 19 were characterized as being needle phobic or having high discomfort around blood draws and injections. Additionally, 26 percent of these needle-phobic children experienced extreme discomfort, the highest level of discomfort, at their last blood draw or injection.
The prevalence of blood draws and injections are high with physician offices and diagnostic laboratories estimated to take more than 900,000 blood draws daily in the U.S.
Despite the high rate of anxiety surrounding procedures, the options for dealing with needle stick pain are limited. The survey found the majority of both adults and children used distraction techniques — such as looking away, humming or focusing on an object — to deal with their discomfort. They found these techniques only moderately effective at best in minimizing their discomfort.
The American Pain Society (APS) and the American Academy of Pediatrics (AAP) set forth guidelines for adequately addressing acute – or short-lived – pain. These guidelines, which apply to the treatment of children and adults, call for healthcare practitioners to eliminate or reduce pain caused by medical treatments whenever possible. In fact, the APS and AAP agree that acute pain experienced with medical procedures can, in most cases, be substantially reduced and even prevented.
About the Survey
On behalf of Vyteris, the survey was conducted by TVG in October and November of 2006. Overall, 11,460 consumers were screened to identify patients with high discomfort levels with venipuncture or injection. A total of 1,010 respondents completed on-line surveys focused on this subject. The national panel from which these consumers were recruited is aligned with the general population across multiple metrics. The overall sampling error for this survey is +/- 3.5%.
About Vyteris, Inc.
Vyteris, Inc., a wholly owned subsidiary of Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN.OB), are the makers of the first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration (FDA). Vyteris’ proprietary active transdermal drug delivery (iontophoresis) technology delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that can result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. Vyteris’ first product, LidoSite(R), which provides dermal analgesia prior to venipuncture (IV catheter insertions, blood draws, etc.) and superficial dermatological procedures, was the first FDA approved active patch. Vyteris has also successfully demonstrated in-vivo, either in animals or in humans, the ability of their active patch technology to deliver drugs transdermally for the following applications: smoking cessation, anti-aging cosmeceuticals, treatments for Parkinson’s disease, and peptides for various indications.
There are several companies who will have their representatives present at the 32nd annual J.P. Morgan Healthcare Conference. J.P. Morgan’s 32nd Annual Healthcare Conference will be held January 13-16, 2014 in San Francisco, California.
Endo Health Solutions (Nasdaq: ENDP) announced that Rajiv De Silva, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 2:00 p.m. Pacific Time.
Express Scripts Holding Company (Nasdaq: ESRX) announced that it will present at the J.P. Morgan Healthcare Conference on January 15, 2014 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) at the Westin St. Francis in San Francisco, CA.
Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China and the parent of Chang’an Hospital, announced that the Company will present at the 32nd Annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2014 at the Westin St. Francis Hotel in San Francisco. Management is scheduled to present at 11:30 a.m. local time on Wednesday, January 15, 2014, and is available to meet with institutional investors at the conference.
Haemonetics Corporation (NYSE: HAE) announced that Brian Concannon, President & CEO, will present at the 32nd Annual J.P. Morgan Health Care Conference in San Francisco on Wednesday, January 15, 2014 at 10:00 am Pacific time / 1:00 pm Eastern time.
Mylan Inc. (Nasdaq: MYL), one of the world’s leading generic and specialty pharmaceutical companies, announced that the Company will present at the J.P. Morgan 32nd Annual Healthcare Conference on Tuesday Jan. 14, 2014, in San Francisco.
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014 in San Francisco. Mike Mahoney, president and chief executive officer, will make a presentation about the company beginning at approximately 9:00 a.m. PT. Following the presentation, Dan Brennan, executive vice president and chief financial officer, and Keith Dawkins, M.D., executive vice president and global chief medical officer, will join Mr. Mahoney in a question and answer session.
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, has acquired Avado, Inc., a developer of cloud-based patient relationship management (PRM) tools and technologies that enable better communication between consumers and health care professionals.
WebMD’s connectivity platform is enabling physicians that use its Medscape mobile app to securely send health education and instructions on thousands of conditions, procedures and drugs to their patients who use WebMD’s mobile app.
“Avado’s innovative technology and tools will complement, and further accelerate WebMD’s efforts to connect patients with their healthcare providers, which is an important first step toward making connected care a reality,” said Bill Pence, WebMD’s Chief Operating Officer and Chief Technology Officer.
Avado is a StartUp Health Company founded in 2010 by serial entrepreneurs Dave Chase, Bassam Saliba and John Yii. Avado’s investors include The Partnership Fund for New York City and several health tech entrepreneurs and investors. The Avado technology has been tested in physician offices and medical centers and this technology will become an important building block of WebMD’s patient-provider connectivity offering.
Avado’s founders Dave Chase and Bassam Saliba will continue with the company and report to Pence. Chase, Saliba and Avado’s engineering talent will remain based in Seattle, WA, and work closely with WebMD’s New York-based connectivity product team.